Daylife Select
A point & click tool to create dynamic content portals. Learn More »
Editor's Picks
There is no pinned content in this Editor's Picks module.
Click here to learn more about content pinning.
-
Former Wyeth sites staying open/Types of future research: - Collegeville, Pa. - some vaccine research continuing, but most other research moving out - Pearl River, N.Y. Full Article at Atlanta Journal Constitution Vendor
-
Pfizer (NYSE: PFE), the world's biggest drugmaker, said Monday it is closing six of its 20 research facilities, reorganizing and consolidating others, and cutting the jobs of roughly 15 percent of its scientists and support staff, according to... Full Article at TransWorldNews
-
Jeffrey B. Kindler, Chairman and Chief Executive Officer of Pfizer, speaks during a news conference with former U.S. President Bill Clinton (L), in New York, August 6, 2009. View Photo »
-
This Chesterfield Village Research Center is truly a world-class facility and our agreement with Pfizer will enable both of our companies to maintain our deep research roots in St. Louis for years to come
SOURCE: Street Insider -
Pfizer Inc. (PFE 11/10/2009 MarketWatch -- Pfizer Inc. said Monday it will "significantly" reduce research and development at some of its sites and shut down six out its 20 sites. Full Article at Biospace
-
Nov. 9 (Bloomberg) -- Pfizer Inc. , the world’s biggest drugmaker, plans to shutter six research centers, following its acquisition of Wyeth. Full Article at Bloomberg.com
-
After successfully closing a merger with Wyeth last month, pharmaceutical colossus Pfizer (PFE) announced plans to close six of its research locations in an effort to consolidate the newly-expanded company’s research operations. Full Article at FOX Business
-
Jeffrey B. Kindler, Chairman and Chief Executive Officer of Pfizer, speaks during a news conference with former U.S. President Bill Clinton (not pictured), in New York, August 6, 2009. View Photo »
-
The ASA has received 48 complaints about the Pfizer TV ad. We are currently assessing the complaints to establish whether or not there are grounds for an investigation.
SOURCE: Brand Republic -
-
Pfizer Inc.’s $68 billion purchase of Wyeth is going to end up costing a number of Triangle workers their jobs. Full Article at Triangle Business Journal
-
ROUSES POINT, N.Y. (AP) - Drug giant Pfizer Inc. is closing three locations in northern New York as it restructures research and development operations following its recent purchase of drug and vaccine maker Wyeth. Full Article at WCAX
About Pfizer Inc.
Wikipedia
There are no results for this module. Edit this module to change the search term used to query Wikipedia
Related Photos
prev
next
-
Reuters Pictures
Jeffrey B. Kindler, Chairman and Chief Executive Officer of Pfizer, speaks during a news conference with former U.S. President Bill Clinton (L), in New York, August 6, 2009.
View Photo » -
Reuters Pictures
Jeffrey B. Kindler, Chairman and Chief Executive Officer of Pfizer, speaks during a news conference with former U.S. President Bill Clinton (not pictured), in New York, August 6, 2009.
View Photo » -
AP Photo
Graphic shows 2008 sales for selected Pfizer drugs.
View Photo » -
AP Photo
Graphic shows 2008 sales for selected Pfizer drugs.
View Photo » -
Reuters Pictures
Jeffrey Kindler (L), Chairman and CEO of Pfizer, and Bernard Poussot, Chairman and CEO of Wyeth, shake hands after a news conference announcing the merger of the two companies in New York, January 26, 2009.
View Photo » -
Reuters Pictures
Jeffrey Kindler, Chairman and CEO of Pfizer, smiles during a news conference announcing the merger of his company with Wyeth in New York, January 26, 2009. Pfizer Inc, the No. 1 drugmaker, said it would acquire U.S. rival Wyeth for about $68 billion in a move to diversify its revenue base.
View Photo » -
Reuters Pictures
Jeffrey Kindler, Chairman and CEO of Pfizer, speaks during a news conference announcing the merger of his company with Wyeth in New York, January 26, 2009. Pfizer Inc, the No. 1 drugmaker, said it would acquire U.S. rival Wyeth for about $68 billion in a move to diversify its revenue base.
View Photo » -
Reuters Pictures
Jeffrey Kindler (L), Chairman and CEO of Pfizer, and Bernard Poussot, Chairman and CEO of Wyeth, shake hands after a news conference announcing the merger of the two companies in New York, January 26, 2009.
View Photo » -
Reuters Pictures
Jeffrey Kindler, Chairman and CEO of Pfizer, smiles during a news conference announcing the merger of his company with Wyeth in New York, January 26, 2009. Pfizer Inc, the No. 1 drugmaker, said it would acquire U.S. rival Wyeth for about $68 billion in a move to diversify its revenue base.
View Photo » -
Reuters Pictures
Jeffrey Kindler (L), Chairman and CEO of Pfizer, and Bernard Poussot, Chairman and CEO of Wyeth, attend a news conference announcing the merger of the two companies in New York, January 26, 2009.
View Photo » -
Reuters Pictures
Jeffrey Kindler, (L) Chairman and CEO of Pfizer and Bernard Poussot, Chairman and CEO of Wyeth, speak during a press conference announcing the merger of the two companies in New York, January 26, 2009.
View Photo » -
Reuters Pictures
Jeffrey Kindler (L), Chairman and CEO of Pfizer, and Bernard Poussot, Chairman and CEO of Wyeth, attend a news conference announcing the merger of the two companies in New York, January 26, 2009.
View Photo » -
Reuters Pictures
Jeffrey Kindler (L), Chairman and CEO of Pfizer, and Bernard Poussot, Chairman and CEO of Wyeth, speak during a news conference announcing the merger of the two companies in New York, January 26, 2009.
View Photo » -
Getty Images
NEW YORK - JANUARY 22: (FILE PHOTO) The Pfizer building is seen January 22, 2007 in New York City.
View Photo » -
Getty Images
NEW YORK - APRIL 17: (FILE PHOTO) Pedestrians walk past the world headquarters of Pfizer Inc. April 17, 2008 in New York City.
View Photo » -
AP Photo
Jeffrey Kindler, chairman and CEO of Pfizer, speaks at a news conference Monday, Jan. 26, 2009, in New York.
View Photo » -
Getty Images
NEW YORK - JANUARY 26: Jeffrey B. Kindler, CEO of Pfizer, appears at a news conference discussing the planned merger of Pfizer and Wyeth January 26, 2009 in New York City. Pfizer plans to acquire Wyeth for $68 billion creating the world's largest biopharmaceutical company.
View Photo » -
Getty Images
NEW YORK - JANUARY 26: Jeffrey B. Kindler, CEO of Pfizer, appears at a news conference discussing the planned merger of Pfizer and Wyeth January 26, 2009 in New York City. Pfizer plans to acquire Wyeth for $68 billion creating the world's largest biopharmaceutical company.
View Photo » -
Getty Images
NEW YORK - JANUARY 26: Jeffrey B. Kindler, CEO of Pfizer (L) and Bernard Poussot, CEO of Wyeth, appear at a news conference discussing the planned merger of their companies January 26, 2009 in New York City.
View Photo » -
Getty Images
NEW YORK - JANUARY 26: Jeffrey B. Kindler, CEO of Pfizer (L) and Bernard Poussot, CEO of Wyeth, appear at a news conference discussing the planned merger of their companies January 26, 2009 in New York City.
View Photo » -
Getty Images
NEW YORK - JANUARY 26: A Pfizer sign hangs on the outside of their headquarters after a news conference discussing the planned merger of Pfizer and Wyeth January 26, 2009 in New York City.
View Photo » -
Getty Images
NEW YORK - JANUARY 26: Jeffrey B. Kindler, CEO of Pfizer (L) and Bernard Poussot, CEO of Wyeth, appear at a news conference discussing the planned merger of their companies January 26, 2009 in New York City.
View Photo » -
Getty Images
NEW YORK - JANUARY 26: Jeffrey B. Kindler, CEO of Pfizer (L) and Bernard Poussot, CEO of Wyeth, appear at a news conference discussing the planned merger of their companies January 26, 2009 in New York City.
View Photo » -
Getty Images
NEW YORK - JANUARY 26: Jeffrey B. Kindler, CEO of Pfizer, appears at a news conference discussing the planned merger of Pfizer and Wyeth January 26, 2009 in New York City. Pfizer plans to acquire Wyeth for $68 billion, creating the world's largest biopharmaceutical company.
View Photo » -
Getty Images
NEW YORK - JANUARY 26: Jeffrey B. Kindler, CEO of Pfizer (L) and Bernard Poussot, CEO of Wyeth, appear at a news conference discussing the planned merger of their companies January 26, 2009 in New York City.
View Photo »
Reuters Pictures
Jeffrey B. Kindler, Chairman and Chief Executive Officer of Pfizer, speaks during a news conference with former U.S. President Bill Clinton (not pictured), in New York, August 6, 2009.
View Photo »Related Topics
Related Videos
Related Quotes
- Previous
- Next
- 1/23
-
This Chesterfield Village Research Center is truly a world-class facility and our agreement with Pfizer will enable both of our companies to maintain our deep research roots in St. Louis for years to come
SOURCE: Street Insider -
The ASA has received 48 complaints about the Pfizer TV ad. We are currently assessing the complaints to establish whether or not there are grounds for an investigation.
SOURCE: Brand Republic -
Legally, Pfizer India and Wyeth India are two separate entities. They have separate boards and will therefore function separately. The products of Pfizer and Wyeth are complementary
SOURCE: Economic Times -
Legally, Pfizer India and Wyeth India are two separate entities. They have separate boards and will therefore function separately. The products of Pfizer and Wyeth are complementary
SOURCE: Economic Times -
As of now, Wyeth and Pfizer are two separate entities and they do not have major overlaps in terms of product portfolios and rather they complement each other
SOURCE: Business Standard -
To fuel the growth of Pfizer in India, we are also expanding our operations in tier-2 and tier-3 cities
SOURCE: Business Standard -
At quarter end, the six largest disclosed long positions in the Partnerships are Arkema, CIT Group debt, Ford Motor Company debt, gold, Lanxess and Pfizer. The Partnerships had an average exposure to equities and fixed income (excluding credit derivatives, gold and foreign currencies) of 99% long and 59...
SOURCE: DealBreaker -
The upgrade of Wyeth's ratings is based on the execution of an unconditional and irrevocable guarantee of Wyeth's outstanding bonds from Pfizer
SOURCE: Newsvine -
We have settled and we are signing an agreement , Kano State government has finally reached a $75 million settlement agreement with Pfizer Pharmaceutical Company, over the 1996 Trovan test in the state
SOURCE: PharmaGossip -
The Board's action continues Pfizer's long tradition of seeking and responding to shareholder input on compensation and other corporate governance topics
SOURCE: Drugs.com -
We are proud to have worked closely with Pfizer on the design and construction of this state-of-the-art facility. Equally important, we are pleased to note that the building was delivered on time and on budget
SOURCE: RedOrbit -
Pfizer financed $22.5 billion in loans from banks that received at least $75 billion from the Treasury Department’s rescue plan.
SOURCE: Pharmalot -
Pfizer recognises the value of our sales and marketing network for the sale of its established products in the pharmacy market in Australia
SOURCE: The Age -
Hopefully [the acquisition of Wyeth] will help supplant the loss of Lipitor [Pfizer's wildly successful cholesterol drug] when it goes off-patent in 2011.
SOURCE: Globe and Mail -
AFER is proud to have the opportunity to honor early career researchers for their achievements through the AFER/Pfizer Ophthalmics Translational Research Awards ... We are grateful for Pfizer Ophthalmics' support and commitment to life-changing ophthalmic research.
SOURCE: Medical News Today -
AFER is proud to have the opportunity to honor early career researchers for their achievements through the AFER/Pfizer Ophthalmics Translational Research Awards ... We are grateful for Pfizer Ophthalmics' support and commitment to life-changing ophthalmic research.
SOURCE: Medical News Today -
Like Carl Camras, Pfizer Ophthalmics is dedicated to making a difference in the lives of patients by collaborating with stakeholders to advance the science and care in the field of eye disorders
SOURCE: Medical News Today -
Pfizer approached Mankind Pharma with a lucrative offer, valuing the India company at $1 billion
SOURCE: Reuters -
The main difference is that the combined marketing power of Pfizer products marketers in Israel is boosted by the merger. Together, we're one of the leading marketers in Israel. The important thing for us is that every Pfizer representative in Israel will also represent the company's values.
SOURCE: Globes Online -
The main difference is that the combined marketing power of Pfizer products marketers in Israel is boosted by the merger. Together, we're one of the leading marketers in Israel. The important thing for us is that every Pfizer representative in Israel will also represent the company's values.
SOURCE: Globes Online -
Caliper Life Sciences is a strategic partner of Pfizer Global Research & Development.
SOURCE: Freshnews.com -
We expect these results to represent a tailwind for large pharma today even though Pfizer's numbers may not translate directly to the rest of the group
SOURCE: Philadelphia Inquirer -
The decision is in the hands of the payer organizations now ... Payers will take a close look at the TRITON data when determining Effient's reimbursement status compared to Plavix. The data create a complex decision-making process. This is not as clear-cut as, say, Pfizer's early strategy with Lipitor.
– 
